Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating

We read with interest the work by Halmos et al 1 in which they describe the effects of dietary FODMAP (Fermentable Oligo-, Di- and Mono- saccharides And Polyols) restriction in patients with IBS on the intestinal microbiota. They showed that low FODMAP intake was associated with reduced total bacterial and lower relative abundance of butyrate-producing Clostridium cluster XIVa, changes that are generally considered unfavourable.2 Therefore, they discourage long-term dietary FODMAP restriction, a suggestion also supported by the recent work of McIntosh and colleagues who noticed unfavourable changes in both microbiota and metabolome of patients with IBS who were on a low FODMAP diet.3 Although low FODMAP intake reduces GI symptoms in almost 75% of patients with IBS, the effects of this diet on the intestinal microbiota might be disadvantageous in the long run. Combining these observations with the important role for the intestinal microbiota in IBS pathogenesis,4 we report here faecal microbiota transplantation (FMT) as an alternative to FODMAP restriction in patients with IBS. We applied FMT in 12 refractory IBS patients (Rome III criteria) with intermittent diarrhoea and severe bloating, …

[1]  J. Raes,et al.  Population-level analysis of gut microbiome variation , 2016, Science.

[2]  A. Benson,et al.  Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[3]  A. Keshteli,et al.  FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial , 2016, Gut.

[4]  J. Raes,et al.  Interindividual differences in response to treatment with butyrate-producing Butyricicoccus pullicaecorum 25-3T studied in an in vitro gut model. , 2015, FEMS microbiology ecology.

[5]  P. Gibson,et al.  Diets that differ in their FODMAP content alter the colonic luminal microenvironment , 2014, Gut.

[6]  M. Pimentel,et al.  Placebo Effect in Clinical Trial Design for Irritable Bowel Syndrome , 2014, Journal of neurogastroenterology and motility.

[7]  P. Bork,et al.  Richness of human gut microbiome correlates with metabolic markers , 2013, Nature.

[8]  Robert C. Edgar,et al.  UPARSE: highly accurate OTU sequences from microbial amplicon reads , 2013, Nature Methods.

[9]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[10]  E. Zoetendal,et al.  Intestinal microbiota in functional bowel disorders: a Rome foundation report , 2012, Gut.

[11]  William A. Walters,et al.  Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms , 2012, The ISME Journal.

[12]  Marcus J Claesson,et al.  An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota , 2011, Gut.

[13]  Rob Knight,et al.  UCHIME improves sensitivity and speed of chimera detection , 2011, Bioinform..

[14]  J. Tiedje,et al.  Naïve Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy , 2007, Applied and Environmental Microbiology.

[15]  Vermeirea,et al.  Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease , 2016 .

[16]  S. Salzberg,et al.  FLASH: fast length adjustment of short reads to improve genome assemblies , 2011, Bioinform..